Cardiology · Pulmonary Arterial HypertensionRegulatory Approvalcommercialmid-term

FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Teva6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 12:32:22 AM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Teva's ANDA for Macitentan introduces a new competitor in the pulmonary arterial hypertension market, which could disrupt pricing and market share for existing therapies. Pharma strategy teams must evaluate the implications for their portfolios and adjust strategies accordingly. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Teva's entry on market dynamics and pricing strategies for similar products. The strongest clinical anchor is Pulmonary Hypertension (PH) Biorepository for Translational Research (ClinicalTrials.gov), sub-indication match (cardiology). In cardiology, 6 regulatory and 1 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). This approval allows Teva to enter the market for Macitentan, potentially increasing competition against existing therapies for pulmonary arterial hypertension.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). While the approval itself is a positive regulatory development for Teva, it may prompt increased scrutiny and regulatory considerations for existing therapies in response to heightened competition.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Teva through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

Teva's entry into the market could significantly affect revenue streams and market positioning for current players in the pulmonary arterial hypertension space, necessitating strategic pricing and marketing adjustments.
Upside for Teva may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Portfolio teams should assess the impact of Teva's entry on market dynamics and pricing strategies for similar products.

What Would Change This Assessment

This becomes more urgent if Monitor market uptake of Teva's Macitentan and any competitive responses from other manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MACITENTAN (ORIG)
FDAmedium relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MACITENTAN (ORIG)
FDAmedium relevance
Entity match (macitentan); Regulatory pathway relevance (nda)
FDA document
View source

Pulmonary Hypertension (PH) Biorepository for Translational Research
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
Effectiveness of Digital Health Application for Primary Hypertension (Liebria)
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369)
Humanexa Signalslow relevance
Sponsor/company relevance (Pfizer)
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Mercklow relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Electroacupuncture for essential hypertension: Mechanistic insights, current clinical evidence, and translational challenges.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
Macitentan

Commercial impact

high

Teva's entry into the market could significantly affect revenue streams and market positioning for current players in the pulmonary arterial hypertension space, necessitating strategic pricing and marketing adjustments.

Regulatory impact

medium

While the approval itself is a positive regulatory development for Teva, it may prompt increased scrutiny and regulatory considerations for existing therapies in response to heightened competition.

What to watch

Monitor market uptake of Teva's Macitentan and any competitive responses from other manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.